Turning Point Therapeutics Announces Appointment of Brian Sun, M.S., J.D., as Incoming General Counsel

$TPTX
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $TPTX alert in real time by email

SAN DIEGO, March 29, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a clinical-stage precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of Brian Sun, M.S., J.D. as its incoming Senior Vice President and General Counsel, effective as of April 11, 2022.

Mr. Sun currently serves as Senior Vice President and General Counsel at Sorrento Therapeutics, Inc, a Nasdaq-listed company, where he leads the legal function and team. Previously, he worked at Prometheus Laboratories and Hologic and served as outside general counsel to early-stage biotechnology companies. Earlier in his career, Mr. Sun worked in private practice at Foley & Lardner LLP. Mr. Sun holds a J.D. from the University of San Diego, an M.S. in Biotechnology from Johns Hopkins University, and a B.A. in Molecular and Cell Biology from the University of California, Berkeley.

"I am excited to welcome Brian to the team. He will be instrumental as we continue to work towards our vision to be the leader in precision oncology," said Athena Countouriotis, M.D., president and CEO. "Brian brings a unique and highly relevant skill set, with deep experience in biotech, and we look forward to his leadership of our legal function and his contributions as a member of the Executive Team."

About Turning Point Therapeutics Inc.

Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company's lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib, which is being studied in a registrational Phase 2 study in adults and a Phase 1/2 study in pediatric patients, has shown antitumor activity and durable responses among kinase inhibitor treatment-naïve and pre-treated patients. The company's pipeline of drug candidates also includes elzovantinib, targeting MET, CSF1R and SRC, which is being studied in a Phase 1 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in MET; TPX-0046, targeting RET, which is being studied in a Phase 1/2 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in RET; and TPX-0131, a next-generation ALK inhibitor, which is being studied in a Phase 1/2 trial of previously treated patients with ALK-positive advanced or metastatic non-small cell lung cancer. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment. For more information, visit www.tptherapeutics.com.

Forward Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and include statements regarding Turning Point Therapeutics being a leader in precision oncology and the potential of Turing Point Therapeutics' drug candidates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "plans", "will", "believes," "anticipates," "expects," "intends," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Turning Point Therapeutics' current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Turning Point Therapeutics' business in general, risks and uncertainties related to the impact of the COVID-19 pandemic to Turning Point Therapeutics' business and the other risks described in Turning Point Therapeutics' filings with the SEC, including its Form 10-K filed with the Securities and Exchange Commission (SEC) on February 28, 2022. All forward-looking statements contained in this press release speak only as of the date on which they were made. Turning Point Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Contact:

Adam D. Levy, PhD., MBA

[ir@tptherapeutics.com]

858-876-3985



Primary Logo

Get the next $TPTX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$TPTX

DatePrice TargetRatingAnalyst
5/20/2022$58.00Buy
BofA Securities
3/1/2022$50.00 → $45.00Hold
Stifel
2/10/2022$120.00 → $85.00Overweight
Wells Fargo
1/21/2022$115.00 → $105.00Outperform
Oppenheimer
12/7/2021Outperform
Cowen & Co.
11/10/2021$150.00 → $115.00Outperform
Oppenheimer
10/12/2021$178.00 → $162.00Buy
HC Wainwright & Co.
10/11/2021Market Outperform → Market Perform
JMP Securities
More analyst ratings

$TPTX
Press Releases

Fastest customizable press release news feed in the world

See more
  • Axonis Therapeutics Announces $115 Million Series A Financing

    -- Oversubscribed financing brings together leading syndicate of life sciences investors -- -- Proceeds to support clinical development of first-in-class therapies for neurological disorders – BOSTON, Oct. 30, 2024 /PRNewswire/ -- Axonis Therapeutics, a biotechnology company focused on the development of novel neuromedicines, announced today the successful completion of an oversubscribed $115 million Series A financing. Proceeds from the financing will be used to advance Axonis' lead development candidate, AXN-027, through clinical proof-of-concept in patients. AXN-027 is a first-in-class oral small molecule designed to potentiate the function of KCC2, a major CNS chloride transporter essent

    $AKRO
    $APLS
    $AUPH
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Specialty Chemicals
    Consumer Durables
  • venBio Raises $528 Million Venture Capital Fund Focused on Life Science Companies

    - venBio promotes Yvonne Yamanaka, Ph.D. to Partner venBio today announced the closing of venBio Global Strategic Fund V ("venBio Fund V"), its fifth life sciences venture capital fund, exceeding its target and closing on approximately $528 million in capital commitments in an oversubscribed fundraise. The firm initiated the fundraise for Fund V in mid-April. Limited partners of Fund V include a broad range of institutional investors comprising sovereign wealth funds, corporate pensions, financial institutions, university endowments, medical institutions, foundations, family offices and funds-of-funds. Under the fund leadership of Managing Partners Richard Gaster, M.D., Ph.D., Corey Goo

    $AKRO
    $APLS
    $AUPH
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Specialty Chemicals
    Consumer Durables
  • NorthStar Medical Technologies, LLC Announces Appointment of Barbara Bodem and David Keeling to Board of Managers

    NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Barbara W. Bodem and David Keeling to its Board of Managers, effective February 12, 2024. Following these appointments, the Board will comprise of 8 directors, 5 of whom are non-executive. "We are pleased to welcome Barbara and David to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar. "Barbara's deep experience serving in senior finance and board roles in leading edge pharmaceutical and

    $BMRN
    $ENOV
    $OPCH
    $SYNH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties
    Medical/Nursing Services

$TPTX
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$TPTX
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$TPTX
SEC Filings

See more

$TPTX
Leadership Updates

Live Leadership Updates

See more
  • NorthStar Medical Technologies, LLC Announces Appointment of Barbara Bodem and David Keeling to Board of Managers

    NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Barbara W. Bodem and David Keeling to its Board of Managers, effective February 12, 2024. Following these appointments, the Board will comprise of 8 directors, 5 of whom are non-executive. "We are pleased to welcome Barbara and David to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar. "Barbara's deep experience serving in senior finance and board roles in leading edge pharmaceutical and

    $BMRN
    $ENOV
    $OPCH
    $SYNH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties
    Medical/Nursing Services
  • Turning Point Therapeutics Announces Appointment of Steve Sabus as Chief Commercial Officer

    SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, today announced the appointment of Steve Sabus as Chief Commercial Officer, effective as of May 31, 2022. Prior to Turning Point, Mr. Sabus spent 15 years in roles with increasing levels of sales responsibility at Astellas Pharma, most recently serving as the Head of Oncology leading a group of over 300 team members. In this role he provided executive leadership to scale the company's $3 billion U.S. oncology franchise by launching and growing new products. His achievements include su

    $TPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Turning Point Therapeutics Announces Appointment of Brian Sun, M.S., J.D., as Incoming General Counsel

    SAN DIEGO, March 29, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a clinical-stage precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of Brian Sun, M.S., J.D. as its incoming Senior Vice President and General Counsel, effective as of April 11, 2022. Mr. Sun currently serves as Senior Vice President and General Counsel at Sorrento Therapeutics, Inc, a Nasdaq-listed company, where he leads the legal function and team. Previously, he worked at Prometheus Laboratories and Hologic and served as outside general counsel to early-stage biotechnology companies. Earlier in his career, Mr

    $TPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$TPTX
Financials

Live finance-specific insights

See more
  • Bristol Myers Squibb Reports Second Quarter Financial Results for 2022

    Reports Second Quarter Revenues of $11.9 Billion, an Increase of 2% YoY; or 5% When Adjusted for Foreign Exchange Posts Second Quarter Earnings Per Share of $0.66 and Non-GAAP EPS of $1.93; Includes Net Impact of ($0.14) per share for GAAP and Non-GAAP EPS Due to Acquired IPRD1 Charges and Licensing Income Delivers Robust Revenue Growth of 11% from In-Line Products and New Product Portfolio; or 16% When Adjusted for Foreign Exchange Expands Oncology Franchise with New Indications for Opdivo and Planned Acquisition of Precision Oncology Company, Turning Point Therapeutics Strengthens Cell Therapy Franchise with Broadest Label for Breyanzi in Relapsed or Refractory Large B-cell Lymph

    $BMY
    $IMTX
    $TPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
  • Turning Point Therapeutics Announces Pipeline Expansion, Licensing of TPX-4589 (LM-302), A Clinical Stage Anti-Claudin18.2 Antibody Drug Conjugate for Gastrointestinal Cancers, From Lanova Medicines

    Strategic Expansion of Turning Point Precision Oncology Portfolio TPX-4589 (LM-302) Currently in Two Ongoing Phase 1 Studies Agreement Includes Potential Broader Scope to Collaborate on up to Three Additional ADC Programs SAN DIEGO, May 05, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, announced today that it has entered into an exclusive license agreement with LaNova Medicines Limited (LaNova) to develop and commercialize LM-302, a novel antibody drug conjugate (ADC) targeting Claudin18.2, in the U.S. and rest of the world, excluding Greater Chi

    $TPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Turning Point Therapeutics Announces Positive Topline Data by Blinded Independent Central Review for Repotrectinib Across All ROS1-Positive NSCLC Cohorts of Phase 1/2 TRIDENT-1 Study

    In a total of 71 TKI-naïve patients, confirmed objective response rate (cORR) of 79% (95% CI: 68, 88)In the TKI-naïve population with approximately 10 months of follow-up, initial estimated durability of response and progression free survival of 85% and 82% at 12-month landmarks, respectivelyIn TKI-pretreated patients, cORR of 42% in those treated with 1 TKI and platinum-based chemotherapy (EXP-2), cORR of 28% in those treated with two TKIs (EXP-3), and cORR of 36% in those treated with 1 TKI (EXP-4) In TKI-pretreated patients with an identified ROS1 G2032R solvent front mutation, cORR of 59%Pre-NDA meeting anticipated this quarter to discuss potential NDA in ROS1-positive NSCLC Conference C

    $TPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$TPTX
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more